Navigation Links
Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
Date:10/17/2007

BOULDER, Colo., Oct. 17 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM) today announced the initiation of an international pivotal Phase 3 clinical trial evaluating amrubicin, the Company's third-generation synthetic anthracycline, in the treatment of second-line small cell lung cancer (SCLC). The randomized, controlled, multi-center study will compare amrubicin to topotecan, the only approved chemotherapy for second-line treatment of SCLC in the US and EU. Enrollment in the study of 480 patients is underway.

Approximately 30,000 patients in the US and 32,000 patients in the EU will be diagnosed with SCLC this year. "The treatment of small cell lung cancer is extremely challenging, given the limited therapeutic options available," said Mark A. Socinski, Associate Professor of Medicine, Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, and a principal investigator in the Phase 3 study. "Preliminary data suggest that amrubicin could represent a significant improvement in the treatment of small cell lung cancer, for which there have been no major medical advances in more than 20 years."

The study compares amrubicin and topotecan in second-line treatment of SCLC patients with sensitive or refractory disease. Sensitive disease is defined as response to first-line platinum-based therapy, with subsequent progression 90 days or more after completion of therapy. Refractory disease is defined as no objective response or progressive disease within 90 days of completion of therapy. Study participants are randomized in a 2:1 ratio to receive either IV amrubicin (40mg/m2 daily for 3 days) or topotecan (1.5 mg/m2 daily for 5 days), both starti
'/>"/>

SOURCE Pharmion Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
2. Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting
3. Malvern initiates European user group meetings for chemical imaging
4. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
7. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
10. Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data
11. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)... Roche announced today that a,comp... perceived pain and,discomfort associated with bl...e monitoring systems and lancing devices were deem... overall, the ACCU-CHEK Aviva and ACCU-CHEK Compac...CCU-CHEK Multiclix, ACCU-CHEK,Softclix and ACCU-C...
(Date:12/1/2008)..., Dec. 1 Genaera Corpor...g of subjects has begun in study MSI-1436C-102 (St...dy of trodusquemine (MSI-1436) in overweight and o...utic for the treatment of type 2 diabetes and obes...late insulin and leptin pathways through the highl...
(Date:12/1/2008)...Newswire-FirstCall/ -- Vical Incorporated (Nasdaq:...llion milestone payment from Merck & Co., Inc....clinical trial of an investigational plasmid DNA (...ed on Vical,s DNA gene delivery technology and enc...). hTERT is the subject of separate license agreem...
(Date:11/28/2008)... Eli Lilly and Company,...Drug Application (sNDA) from,the U.S. Food and Dr...e HCl),for the management of chronic pain. Lilly ...lf of 2009, adding data from a recently completed ...the knee. , The decision does not affect du...
Breaking Medicine Technology:Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful 2Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful 3Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 2Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 3Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4ChemAxon and Agilent Technologies Sign Agreement Extending JChem Integration With Kalabie Electronic Lab Notebook 722 1ChemAxon and Agilent Technologies Sign Agreement Extending JChem Integration With Kalabie Electronic Lab Notebook 722 2Norditropin 28R 29 Approved for Treatment of Children with Short Stature Associated with Turner Syndrome 343 1Norditropin 28R 29 Approved for Treatment of Children with Short Stature Associated with Turner Syndrome 343 2Norditropin 28R 29 Approved for Treatment of Children with Short Stature Associated with Turner Syndrome 343 3Norditropin 28R 29 Approved for Treatment of Children with Short Stature Associated with Turner Syndrome 343 4Norditropin 28R 29 Approved for Treatment of Children with Short Stature Associated with Turner Syndrome 343 5Norditropin 28R 29 Approved for Treatment of Children with Short Stature Associated with Turner Syndrome 343 6Multiple corticosteroid injections in pregnant women may increase cerebral palsy 1712 1Multiple corticosteroid injections in pregnant women may increase cerebral palsy 1712 2Is there really a mommy gene in women 3F 1708 1Is there really a mommy gene in women 3F 1708 2
...007 /PRNewswire-FirstCall/ --,SuperGen, Inc. today...ficer, will present at the C.E. Unterberg, Towbin ...ay, July 12, 2007 at the Mandarin,Oriental Hotel i...C.E. Unterberg, Towbin Emerging,Growth Opportuniti...DT. A live webcast of the presentation will be ava...
...07 /PRNewswire-FirstCall/ -- Micromet,Inc. , a bi...t of,novel, proprietary antibody-based products fo...day announced that Dr. Christian Itin,President a...,present at the 3rd Annual C.E. Unterberg, Towbin ..., July 12, 2007 at 10:00am,eastern. , A webcast o...
Other Medicine Technology:SuperGen to Present at the C.E. Unterberg, Towbin Emerging Growth,Opportunities Conference 2Micromet, Inc. to Present at the 3rd Annual C.E. Unterberg, Towbin,Emerging Growth Conference 2
(Date:12/1/2008)...all/ -- ViroPharma Incorporated,(Nasdaq: VPHM )...lemental,Biologics License Application (sBLA) to ...inryze(TM) C1 Inhibitor (human) as a treatment for... The sBLA is based on a re-analysis and resu...atment study of Cinryze and interim data from an o...
(Date:12/1/2008)...lnesses common, study shows , , MONDAY,...are common among young adults in the United States... To reach this finding, U.S. researchers analyzed ...25, who took part in the National Epidemiologic Su...tudy found that 45.8 percent of the 2,188 college ...
(Date:12/1/2008)...er Institute,s cancer registry has found that as m...or incomplete radiation treatment following breast... can lead to worse outcomes. , Dr. Heather Taffe...gues found that among a nationally representative ...ents aged 65 and older, almost 1,300 women experie...
(Date:12/1/2008)...wire/ -- Americans United for Life (AUL) today a...resolution opposing the federal "Freedom of Choice...pt the resolution immediately when they convene th... AUL President & CEO said, "The so-called ,Fre...protects and promotes the abortion industry, sacri...
Breaking Medicine News(10 mins):Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 2Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 3Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 4Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 5Health News:Few Young Adults Seek Treatment for Psych Disorders 2Health News:Delays in radiation therapy lead to increased breast cancer recurrence 2Health News:Americans United for Life Urges State Legislatures to Oppose Federal Power Grab: Provides Model Resolution Denouncing Freedom of Choice Act (FOCA) 2
...the children who are exposed to cats soon after bi...n inflammatory condition that causes the skin// to...nted at the American Thoracic Society Internationa...sed to two or more dogs at home suggested a slight...
...ra have announced that, they are taking preventive...laria from the past three months//. A senior hea...scheduled to visit Tripura to assess the situation...th reports of drug resistance. He also stated tha...
...octors of Sir Sunderlal hospital in the Banaras Hi... strike// for the second consecutive day today to ... the backward castes in the higher education insti...strike, the agitating doctors formed human chain o...
... was said that 44 % of women suffer from Intimate ...affects both the mental health as well as the phys...d by senior investigators of the Group Health Cent...nalyzed 3,400 women members. The researchers found...
Other Medicine News:Health News:Children Having An Early Exposure To Cats May Develop Eczema 2
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
Medicine Products: